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Introduction
Cytokines collectively play key roles in the regulation of 
systemic inﬂ   ammation, local tissue damage, and 
immuno  modulation. Not surprisingly, cytokines often 
play direct roles in disease pathogenesis, including that of 
systemic lupus erythematosus (SLE). To the chagrin of 
both investigator and practitioner, the eﬀ  ects of cytokines 
are pleiotropic and include both synergistic and 
antagonistic eﬀ   ects on other cytokines – thereby 
introducing tremen  dous complexity that has often led to 
diametrically oppos  ing conclusions in diﬀ  erent studies. 
In the present review, we focus on four cytokines that 
have received great attention either as candidate bio-
markers for disease activity and/or as candidate targets of 
novel biologic agents.
Interleukin-6
General biology of IL-6
IL-6 is a pleiotropic 26 kDa protein produced by a panoply 
of cell types, and aﬀ  ects the function of an equally broad 
spectrum of cell types. Of greatest relevance to SLE is the 
ability of IL-6 to promote activation and/or diﬀ  erentiation 
of cells central to the development of systemic auto-
immunity and the attendant pathologic inﬂ  ammatory 
responses, including T cells, B cells, macrophages, and 
neutrophils [1].
IL-6 signal transduction occurs via coordinated inter-
actions between the 80 kDa IL-6 binding chain (IL-6 
receptor (IL-6R), IL-6R α chain, CD126) and the 130 kDa 
signal transducing chain (gp130, IL-6R β chain, CD130). 
IL-6 can bind to membrane IL-6R, thereby inducing 
homodimerization of gp130 and leading to activation of 
gp130-associated JAK1 and tyrosine phosphorylation of 
gp130. Alternatively (and not mutually exclusively), IL-6R 
can be enzymatically cleaved from the cell surface, 
thereby producing soluble IL-6R. Soluble IL-6R can then 
bind circulating IL-6 and form IL-6/IL-6R complexes that 
act on cells expressing gp130 [1].
IL-6 in murine systemic lupus erythematosus
Studies in multiple murine SLE models point to an essen-
tial role for the IL-6 pathway in SLE. Genetic deﬁ  ciency 
of IL-6 in MRL/lpr mice delays disease development, 
reduces CD4+ and CD8+ T-cell numbers, decreases 
glomerular IgG and C3 deposition, downregulates renal 
parenchymal vascular cell adhesion molecule-1 (VCAM-1) 
expression, and diminishes kidney macro  phage inﬁ  ltra-
tion [2]. Th   is last eﬀ  ect may be especially impor  tant, in as 
much as a close association between activated renal 
macrophages and disease has been documented in 
(NZB x NZW)F1 (BWF) mice [3].
Additional important observations have been made 
with BWF mice. Exogenous IL-6 increases IgG anti-DNA 
autoantibody production by B cells isolated from clini-
cally aﬀ  ected BWF mice, whereas neutralization of IL-6 
via either addition of an anti-IL-6 mAb or macrophage 
depletion decreases production of such autoantibodies 
[4-6]. Building on these ex vivo ﬁ  ndings, administration 
of human IL-6 to 6-month-old female BWF mice 
promoted accelerated membranoproliferative glomerulo-
nephritis associated with marked upregulation of 
mesangial MHC class II antigens and glomerular inter-
cellular adhesion molecule-1 (ICAM-1) expression. 
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glo  merulo  nephritis, distinguishing the eﬀ  ects of IL-6 on 
systemic inﬂ   ammation from its direct eﬀ   ect on renal 
mesangial cells [7]. More impressive were the signiﬁ  cant 
decreases in mortality, progression of proteinuria, and 
anti-dsDNA antibody levels in BWF mice chronically 
treated from 3 months of age with anti-IL-6 mAb or anti-
IL6 receptor antibody [8,9].
IL-6 is also associated with SLE in other murine SLE 
models. In pristine-induced SLE, renal disease was 
milder, and high levels of IgG anti-single-strand DNA, 
anti-dsDNA, and anti-chromatin antibodies were absent 
in IL-6-deﬁ  cient mice [10]. In JunBΔep mice, development 
of an SLE-like phenotype (including skin lesions and 
immune complex glomerulonephritis) was linked to 
increased epidermal IL-6 secretion that arose from the 
speciﬁ  c loss of epidermal JunB. Intercrosses with IL-6-
deﬁ  cient mice abrogated the SLE phenotype [11].
IL-6 in human systemic lupus erythematosus
As in murine SLE, serum levels of IL-6 are elevated in 
human SLE and have correlated with disease activity or 
anti-dsDNA levels in some studies [12-14]. Th  e  increased 
frequency of IL-6-producing peripheral blood mono-
nuclear cells correlates with disease severity/activity and 
treatment response [15,16]. Of note, SLE B cells express 
IL-6R spontaneously and produce great amounts of IL-6 
[17,18]. Moreover, autoreactive T-cell clones from SLE 
patients also produce large amounts of IL-6, and thereby 
promote B-cell activation and autoantibody pro  duc  tion 
[19]. Indeed, the copious spontaneous pro  duc  tion of 
immunoglobulin by SLE B cells can be enhanced by 
exogenous IL-6 and diminished by neutralizing anti-
bodies to IL-6 [13].
Aside from its systemic eﬀ  ects, IL-6 is closely linked 
with speciﬁ   c disease manifestations. Elevated cerebral 
spinal ﬂ  uid levels of IL-6 are found in SLE patients with 
psychosis and may aﬀ   ord an eﬀ   ective measure of its 
diagnosis [20]. In SLE nephritis patients, urinary levels of 
IL-6 are elevated, correlate with titers of anti-dsDNA 
anti  bodies, and decrease following treatment [14,21]. 
Local expression of IL-6 was documented in kidney 
tissue of SLE nephritis patients [22], arising at least in 
part from mesangial cells [23].
Therapeutic blockade of IL-6 in systemic lupus 
erythematosus
Given the considerable evidence pointing to a contri  bu-
tory role for IL-6 in SLE pathogenesis, the a priori 
likelihood that therapeutic targeting of this pathway in SLE 
will be eﬃ   cacious is high. Tocilizumab, a mouse–human 
chimeric anti-human anti-IL-6R mAb, is already US Food 
and Drug Administration approved for the treatment of 
patients with rheumatoid arthritis. Tocilizu  mab eﬀ  ectively 
inhibits IL-6 signal transduction by its ability to bind 
both mIL-6R (preventing IL-6 binding to cell-surface 
mIL-6R/gp130 complex) and sIL-6R (pre  vent  ing 
formation of IL-6/sIL-6R complex, which could bind to 
cell-surface gp130).
Although initial results suggest that tocilizumab can 
control SLE disease activity, an increased risk of 
infections may limit its ultimate clinical utility. In an 
open-label phase I dosage-escalation study (Table 1), 16 
patients with mild to moderate disease activity (presence 
of chronic glomerulonephritis or extrarenal SLE Disease 
Activity Index – SELENA modiﬁ  cation score of 3 to 10) 
received one of three doses of tocilizumab (2, 4, or 8 mg/
kg) every other week for 12 weeks [24]. Disease activity 
showed improvement, with a decrease of ≥4  points in 
activity scores for eight of 15 evaluable patients. 
Additionally, arthritis improved in all seven patients who 
had arthritis at baseline, and completely resolved in four 
of them. Th  ere were also signiﬁ   cant decreases in the 
frequency of circulating plasma cells and in levels of anti-
dsDNA antibodies. Tocilizumab also led to a similar 
decline in levels of C3 and the complement activation 
products, iC3b and C5b-9 (terminal activation complex). 
Tocilizumab treatment led to dose-related decreases in 
the absolute neutrophil count, however, with two patients 
experiencing severe neutropenia (absolute neutrophil 
count  of 500 to 1,000/μl). Th  e decline in neutrophil 
counts probably had clinical consequences – 16 infec  tions 
developed in 11 patients, 10 of whom required systemic 
antibiotics or antivirals. Additional studies are clearly 
needed before tocilizumab or other IL-6 antagonists can 
be considered viable therapeutics in human SLE.
Tumor necrosis factor alpha
General biology of TNFα
TNFα is expressed as a 26 kDa transmembrane protein 
that can be cleaved by TNFα-converting enzyme to 
release a 17 kDa soluble protein [25]. Like IL-6, TNFα is 
produced by a variety of cells, including activated macro-
phages and monocytes as well as B cells, T cells, keratino-
cytes, renal cells, and ﬁ  broblasts.
Depending upon the conditions, TNFα can trigger 
either proinﬂ  ammatory or anti-inﬂ  ammatory pathways 
by engaging one or both of two distinct transmembrane 
receptors: the type I, p55 tumor necrosis factor receptor 
(TNFR1), and the type II, p75 TNFR (TNFR2) [26]. 
TNFR1 may trigger apoptotic and anti-inﬂ  ammatory 
signals through Fas-associated death domain (FADD) 
and activa  tion of the caspase cascade. Conversely, it may 
also trigger anti-apoptotic and proinﬂ  ammatory respon-
ses through recruitment of TNF receptor-associated 
factor 2 (TRAF-2), which activates NF-κB, c-Jun NH2-
terminal kinase (JNK), and mitogen-activated protein 
(MAP) kinase. Binding of TNFα to TNFR2 also leads to 
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responses. Th   e TNF/TNFR system can thus serve dually 
both as a potent pro  inﬂ  am  matory mediator and as a key 
immune modulator as a function of the immuno  logical 
setting [25,26].
TNFα in murine systemic lupus erythematosus
Several studies point to a pathogenic role for TNFα in 
murine SLE. TNFα expression is increased in the sera 
and kidneys of MRL/lpr mice and correlates with disease 
activity [27,28]. Indeed, TNF antagonism/inhibition in 
such mice has clinical beneﬁ  t. Furthermore, in C3H.SW 
mice with induced SLE, treatment with anti-TNFα mAb 
results in decreased development of anti-DNA anti-
bodies, proteinuria, and glomerular immune-complex 
deposition [29,30].
In sharp contrast, the administration of recombinant 
TNFα or TNFα-inducing agents to BWF mice is clearly 
beneﬁ  cial [31-33]. Moreover, TNFα deﬁ  ciency in other 
SLE mice has resulted in disease induction/exacerbation. 
Autoimmunity and fatal SLE nephritis develop in NZB 
mice when crossed with TNFα-deﬁ   cient mice [34]. 
Similarly, TNFα deﬁ   ciency in mice bearing a mixed 
B6/129 genetic background (H-2b/b) develop IgG2b and 
IgG3 anti-DNA antibodies, glomerular IgG deposition, 
and alterations in glomerular structure resembling SLE 
nephritis [35].
Th  ese often conﬂ  icting  eﬀ   ects of TNFα in diﬀ  erent 
murine SLE models underscore this cytokine’s dual 
proinﬂ   ammatory and immunoregulatory roles. Th  ese 
conﬂ  icting eﬀ  ects are also disease stage speciﬁ  c and may 
reﬂ  ect the cell type expressing the receptors as well as 
diﬀ  erential expression of the receptors themselves by a 
given cell type. Although the underlying molecular and 
cellular mechanisms remain largely enigmatic, at least 
part of TNF’s functional duality might segregate at the 
level of the two TNFα receptors [35,36]. Indeed, in anti-
GBM antibody-induced glomerulonephritis, TNFR2 
deﬁ  ciency is protective, whereas TNFR1-deﬁ  cient mice 
develop proteinuria and renal pathology similar to those 
in wild-type controls [37]. In addition, TNFR1 deﬁ  ciency 
greatly accelerates lymphoadenopathy, autoantibody 
produc  tion, and mortality in C57BL/6-lpr mice [38]. In 
NZM2328 mice singly deﬁ  cient in one TNFR, however, 
signaling through the other receptor can compensate and 
permit persistence of the wild-type clinical and patho-
logical phenotypes. Deletion of both receptors, with 
complete abrogation of TNFα signaling, results in 
signiﬁ  cantly accelerated disease [39].
TNFα in human systemic lupus erythematosus
As in animal models, the evidence has been conﬂ  icting 
regarding the role of TNFα in human SLE. Some studies 
have shown that serum TNFα levels are elevated in SLE 
patients and correlate with disease activity [40,41]. Other 
studies, however, have shown otherwise. One study 
demonstrated that elevated TNFα plasma levels do not 
correlate with SLE disease activity, and another study 
showed that TNFα levels were actually higher in patients 
with inactive disease, suggesting a protective role for 
TNFα in SLE [42,43]. Diﬀ  erences in patient charac  ter-
istics, assays for TNFα, and study designs probably each 
contribute to the somewhat inchoate picture that 
emerges, highlighting the pleiotropic and oftentimes 
unpredictable nature of TNFα.
In addition to systemic production of TNFα, local 
production of TNFα may contribute to SLE. Studies of 
local production of TNFα in the kidneys have docu-
mented upregulated TNFα protein and gene expression 
in renal biopsy tissue from 52% of SLE nephritis patients 
[22]. Local upregulated TNFα protein and gene expres-
sion within the resident glomerular, tubular, and 
mesangial cells has also been demonstrated [23].
Th  e eﬀ   ects of systemically produced TNFα may be 
dissociated from the eﬀ  ects of locally produced TNFα. 
For example, DR3-positive or DR4-positive SLE patients, 
who genetically are high TNFα producers in response to 
appropriate induction, are not predisposed to nephritis. 
In contrast, DR2 and DQw1-positive SLE patients, who 
genetically are low TNFα producers following induction, 
have an increased incidence of SLE nephritis [44]. As 
another example, the TNFα adaptor proteins TNF 
receptor type 1-associated DEATH domain (TRADD), 
FADD, receptor interacting protein-1 (RIP-1), and 
Table 1. Cytokine-targeting agents and their clinical trials in SLE
Cytokine target  Therapeutic agent  Stage of clinical trial  References
IL-6 Tocilizumab  Phase  I  [24]
TNFα  Infl  iximab, etanercept  Phase I; phase II and III trials terminated prematurely  [53-55]
IFNα  Sifalimumab (MEDI-545), rontalizumab (rhuMab)  Phase I; phase II ongoing  [102,103]
BLyS  Belimumab  Phase III completed  [115-121]
  A-623  Phase I; phase II suspended/restarted  [123]
  LY2127399  Phase III planned  [125]
BLyS and APRIL  Atacicept  Phase II/III initiated  [122]
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mono  nuclear cells, and their decreased expres  sion 
correlates with disease activity [45]. Th  e  down  regulation 
of TRADD and FADD (which can recruit the caspase 
cascade) may thus promote an anti-apoptotic eﬀ  ect that 
leads to survival of autoreactive cells. Of note, TRADD, 
RIP-1, and TRAF-2 (which can activate the NF-κB 
pathway) are upregulated, rather than down  regulated, in 
renal tissue from SLE nephritis patients, suggesting that 
TNFα may promote immunoregulatory functions 
systemically but may mediate inﬂ  ammation locally [46].
Therapeutic blockade of TNFα in systemic lupus 
erythematosus
Use of TNFα antagonists is well established in the 
treatment of rheumatoid arthritis, juvenile idiopathic 
arthritis, psoriatic arthritis, chronic inﬂ  ammatory bowel 
disease, and ankylosing spondylitis [47]. Consistent with 
the competing proinﬂ  ammatory and anti-inﬂ  ammatory 
eﬀ  ects of TNFα, use of TNFα antagonists in multiple 
sclerosis patients has led to immune activation and 
disease exacerbation [48]. Moreover, TNFα antagonists 
have triggered the development of autoantibodies, 
neuroinﬂ  ammatory disease, or SLE-like features in some 
patients with rheumatoid arthritis or chronic inﬂ  amma-
tory bowel disease [49-51]. Indeed, depending on the 
disease, two-thirds of previously antinuclear antibody 
(ANA)-negative patients became ANA-positive after 
initiation of TNFα-antagonist therapy. A recent report 
described six rheumatoid arthritis patients who 
developed active SLE associated with major organ 
involve  ment and life-threatening manifestations and 
required additional treatment beyond cessation of the 
TNFα-antagonist regimen [52].
Nevertheless, TNFα-antagonist therapy has been success-
ful in some SLE patients. Six patients with moderately 
active SLE (three with nephritis, two with arthritis 
refractory to other therapies, and one with both joint and 
renal involvement) were given four infusions of 300 mg 
doses of inﬂ   iximab, in combination with immuno-
suppression with azathioprine or methotrexate [53]. 
Patients with joint involvement experienced remission of 
arthritis, which relapsed 8 to 11 weeks after the last 
inﬂ  iximab infusion. In the four patients with nephritis, 
proteinuria decreased by >60% within 8 weeks. Of note, 
anti-dsDNA and anti-cardiolipin antibodies increased in 
four patients. A number of long-term studies also 
revealed modest clinical beneﬁ  t, but there were several 
adverse events, including deep-vein thrombosis, infec-
tions, central nervous system lymphoma, and Legionella 
pneumonia [54,55].
Th  e need to evaluate safety and eﬃ   cacy  of  TNFα 
blockade in SLE prompted two large randomized phase II 
and phase III trials with etanercept and inﬂ  iximab 
(Table  1), but both studies (NCT00447265 and 
NCT00368264) were terminated prematurely (although 
this may have had more to do with corporate business 
matters than with medical matters). As with neutrali-
zation of IL-6, additional studies with TNFα antagonists 
will be needed before use of such agents becomes a 
routinely viable option in human SLE.
Type I interferons
General biology of type I interferon
Type I interferon represent a large family of cytokines 
that includes many IFNα subtypes, a single IFNβ, and 
multiple IFNω subtypes that exert their expansive 
biological properties through engagement of a common 
heterodimeric receptor (type I interferon receptor 
(IFNAR)) composed of IFNAR1 and IFNAR2 subunits. 
Th  ese broad eﬀ   ects include activating dendritic cells; 
promoting prolifera  tion, survival, and diﬀ  erentiation of 
monocytes into antigen-presenting cells and B cells into 
plasma cells; stimulating the Th   1 pathway and preventing 
apoptosis of activated cytotoxic T cells; and suppressing 
regulatory T cells, enhancing natural killer cell activity, 
and modulating each of these cells’ respective cytokine 
production and signaling responses.
Within the type I interferon family, the IFNα subtypes 
are arguably the biologically most important in general, 
and this certainly is the case for SLE. Th  e major 
producers of IFNα are plasmacytoid dendritic cells, 
although virtually any cell type can elaborate interferon 
[56]. IFNα is produced both in response to exogenous 
stimuli, such as bacterial and viral pathogens, and to 
endogenous stimuli, such as self-nucleic acids and nucleic 
acid-containing immune complexes, via Toll-like 
receptor (TLR)-dependent and TLR-independent path-
ways. Among the TLR-dependent pathways, engagement 
of TLR7 and TLR8 by single-strand RNA-containing 
complexes and engagement of TLR9 by dsDNA-con-
taining complexes may be especially relevant to SLE 
pathogenesis [56].
Type I interferon in murine lupus
Numerous studies have collectively demonstrated the 
complexity of the type I interferon/IFNAR axis in the 
pathogenesis of murine SLE. In several strains of mice 
with SLE-related autoimmune phenotypes, type I 
interferon/IFNAR signaling promotes autoantibody pro-
duc  tion and development of renal disease. Indeed, 
genetic deletion of the Ifnar1 gene prevents the develop-
ment of severe clinical and pathological disease in SLE-
prone NZB and NZM2328 mice [57,58]. Similarly, up-
regulation or administration of IFNα to BWF mice, 
(NZWxBXSB)F1 mice, B6.Sle123 mice, or NZM2328 
mice markedly accelerates nephritis and death [59-61], 
and in BWF mice is associated with unabated expansion 
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interferon/IFNAR signaling is not always deleterious. 
IFNAR-deﬁ   cient MRL/lpr mice develop more severe 
disease than do their IFNAR-suﬃ   cient counterparts [63], 
an observation that may relate to the ability of IFNβ to 
ameliorate disease manifestations in MRL/lpr mice. 
Importantly, these counterintuitive eﬀ   ects of type I 
interferon are not limited to MRL/lpr mice, in that 
blockade of type I interferon in B57BL/6 or B6.Sle2 mice 
led to increased, rather than decreased, levels of IgG 
autoantibodies [64].
In addition to studies that directly manipulated type I 
interferon and/or IFNAR expression, studies focused on 
TLR (especially TLR7 and TLR9) have also pointed to a 
vital role for IFNα in murine SLE. Interestingly, TLR7/9 
doubly-deﬁ   cient MRL/lpr mice display signiﬁ  cantly 
reduced ANA titers, proteinuria, and kidney disease [65]. 
In agreement with these results, treatment of BWF mice 
with a dual inhibitor of TLR7 and TLR9 demonstrated 
signiﬁ  cant reductions in interferon produced by plasma-
cytoid dendritic cells; decreased proteinuria; reduced 
glomerulonephritis, serum autoantibody levels, and end-
organ damage; and increased survival [66]. Indeed, 
adminis  tration of bacterial or viral TLR ligands to SLE-
prone mice leads to increased IFNα production and 
disease exacerbation, whereas disease is not exacerbated 
in similarly treated IFNAR-deﬁ  cient SLE-prone mice [67].
Type I interferon and human systemic lupus 
erythematosus
Serum type I interferon activity is increased in SLE 
patients and their ﬁ  rst-degree relatives, and ages of peak 
type I interferon are associated with ages of peak SLE 
incidence [68,69]. Type I interferon levels have correlated 
with disease activity in a number of cross-sectional 
studies, although longitudinal correlations could not be 
established in other studies [70-72]. Th   e use of elevated 
serum levels of type I interferon-regulated chemokines as 
biomarkers for disease activity was suggested in early 
studies [73] and was later replicated and validated by 
associations between elevated transcript levels of these 
chemokines with disease activity and organ damage 
[74,75]. By relying on expression of type I interferon-
inducible genes rather than on circulating type I inter-
feron protein levels (which are often barely detectable or 
not detectable), most SLE patients have been demon-
strated to unequivocally express type I interferon-
inducible genes in peripheral blood mononuclear cells. 
Th   is so-called interferon signature has been convincingly 
correlated with active disease, renal manifestations, and 
increased damage index [70,76,77]. Furthermore, the 
interferon gene signature has been found in glomerular 
and synovial tissue, suggesting local organ involvement of 
type I interferon [78,79]. Indeed, plasmacytoid dendritic 
cells – the main producers of IFNα – accumulate in the 
glomeruli of SLE nephritis patients and can also be found 
in cutaneous lesions where they promote continuous 
IFNα release [80,81].
In terms of potential interferon contribution to 
lymphocyte autoreactivity in SLE, interferon not only 
promotes B-cell activation, antibody production, and 
class switching, but can also decrease B-cell selectivity 
for CpG-rich DNA, thereby activating TLR9, and can 
also allow stimulation of B cells by non-CpG DNA 
[82,83]. Moreover, interferon can potentially promote 
survival of autoreactive B cells, since it can prevent B-cell 
apoptosis and enhance proliferation even in the absence 
of mitogenic stimuli [84].
T-cell function is also modulated by interferon in SLE. 
Ample literature has demonstrated dysfunction of regu-
la  tory T cells in SLE, with SLE regulatory T cells being 
ineﬃ   cient suppressors of inﬂ  ammation and T-cell pro-
lifera  tion [85,86]. Part of this dysfunction appears to be 
due to interferon production by antigen-presenting cells 
[87].
Th  e  ex vivo and in vitro ﬁ  ndings that suggest a role for 
type I interferon in SLE pathogenesis are supported by 
the development of SLE or SLE-like syndromes (malar 
rash, oral ulcers, photosensitivity, renal involvement, and 
anti-Sm and anti-dsDNA antibodies) following adminis-
tration of IFNα [88,89]. Occasionally, IFNα-induced SLE 
has led to life-threatening multiorgan involvement [90].
Recent investigations into the genetics of SLE have also 
revealed a strong connection between the type I 
interferon pathway and SLE. Th  e gene coding for the 
transcription factor IRF5 was the ﬁ  rst gene involved in 
IFNα production to be associated with SLE susceptibility 
[91]. Further evidence of genetic association between 
SLE and IRF5 and for interaction between IRF5 and 
TYK2, a Janus kinase involved in cytokine signaling that 
binds to IFNAR, has also been demonstrated [92]. 
Moreover, IRF5 risk loci are also associated with high 
serum type I interferon activity and the development of 
autoantibodies to dsDNA and RNA-binding proteins. 
[93]. Subsequently, the related IRF7 has also been asso-
ciated with SLE [94]. Furthermore, the STAT4 gene, 
which codes for a protein that interacts with the cyto-
plasmic portion of IFNAR, is strongly associated with 
SLE. STAT4 risk loci increase sensitivity to IFNα, are 
associated with a more severe phenotype that includes 
anti-dsDNA antibodies and renal involvement, and inter-
act with IRF5 susceptibility loci [95-97]. Another SLE 
susceptibility gene codes for IRAK1, which is involved in 
TLR-triggered signal transduction [98].
IFNα, independent of its eﬀ  ects on the immune system, 
may be especially important in promoting atherosclerotic 
disease in SLE. Th   e dysfunction of circulating endothelial 
progenitor cells and myelomonocytic circulating 
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in as much as neutralization of IFNα restores a normal 
endo  thelial progenitor cell/circulating angiogenic cell 
pheno  type [99]. Indeed, SLE patients with robust 
interferon signatures have decreased endothelial function 
[100], and interferon signatures correlate with carotid 
intima media thickness [101].
Therapeutic blockade of type I interferon in systemic lupus 
erythematosus
Th  e fact that type I interferon exacerbates SLE in some 
mouse strains but ameliorates SLE in others [59-61,63] 
raises the possibility that markedly divergent clinical 
responses to type I interferon antagonists might emerge 
among individual SLE patients. Experience to date with 
antagonists against type I interferon in SLE is very limited 
(Table 1). Treatment of SLE patients (n = 62) in a phase I 
trial with anti-IFNα mAb sifalimumab (MEDI-545) in 
single escalating intravenous doses of 0.3, 1.0, 3.0, 10.0, or 
30.0 mg/kg led to dose-dependent reversal of the inter-
feron signature in both the blood and skin, down  regu-
lation of several cytokines, and reduced disease activity 
without any increase in serious infections [102]. Results 
from a phase I trial with the anti-IFNα mAb rontalizumab 
(rhuMab IFN-α) in SLE patients (n = 32) replicated this 
dose-dependent reduction in the interferon signature 
[103]. Two phase II trials are currently ongoing to 
evaluate the eﬀ  ects of anti-IFNα in SLE (NCT01031836 
and NCT00657189), but as yet it will be some time before 
the utility of type I interferon antagonists in SLE is known.
B-lymphocyte stimulator
General biology of BLyS
BLyS (also known as BAFF) is a cytokine that is essential 
for survival of most B cells beyond the transitional 1 stage 
[104]. BLyS binds to three receptors: BCMA, TACI, and 
BR3 (also known as BAFFR). Two of these receptors 
(BCMA and TACI), but not the third (BR3), also bind 
APRIL, a cytokine closely related to BLyS that shares 
some, but not all, of its biological properties. Whereas 
survival of plasma cells, which express TACI and BCMA, 
is supported by either BLyS or APRIL, the survival of pre-
plasmablast mature B cells, which express much BR3 but 
little TACI and essentially no BCMA, is supported only 
by BLyS. Of note, memory B cells appear to be indepen-
dent of both BLyS and APRIL.
In addition to aﬀ  ecting B-cell survival/function, BLyS 
can aﬀ  ect other cell types that express BLyS receptors. 
Speciﬁ  cally, BR3 is expressed on T cells, although its role 
in T-cell signaling/stimulation is controversial [104]. 
Moreover, dendritic cells also express BLyS receptors, 
and BLyS-stimulated dendritic cells upregulate co-stimu-
latory molecules and produce inﬂ  ammatory  cytokines 
and chemokines such as IL-1, IL-6, CCL2, and CCL5.
BLyS in murine systemic lupus erythematosus
Th  ere is an irrefutable link between BLyS and murine 
SLE. Constitutive overexpression of BLyS in BLyS-trans-
genic nonautoimmune-prone mice leads to SLE-like 
features, including elevated levels of multiple auto  anti-
bodies (including anti-dsDNA), circulating immune 
complexes, and glomerular immunoglobulin deposition 
[105]. Moreover, BLyS overexpression accelerates the 
development of SLE-like features in mice that bear an 
autoimmune diathesis but otherwise do not develop 
overt SLE [106]. On the other hand, SLE-prone 
NZM2328 mice genetically deﬁ  cient in BLyS are largely 
spared from overt disease (severe proteinuria and 
premature death), although the lifelong absence of BLyS 
does not protect them from ultimately developing sero-
logical autoimmunity and renal pathology [107]. Most 
importantly, treatment of BWF mice, (NZMxBXSB)F1 
mice, MRL/lpr mice, or NZM2410 mice with either 
TACI-Ig (which neutralizes both BLyS and APRIL) or 
BR3-Ig (which selectively neutralizes BLyS) is eﬀ  ective at 
preventing clinical disease and ameliorating renal injury 
[108]. Intriguingly, IFNα-driven exaggerated disease in 
several SLE-prone mouse strains is associated with 
increases in serum BLyS levels [59-61], and IFNα-driven 
exaggerated disease is completely blocked in BLyS-
deﬁ  cient NZM2328 mice [109], indicating that BLyS is a 
vital contributor to the IFNα-driven pathogenic pathway 
in SLE.
BLyS in human systemic lupus erythematosus
Not only is BLyS associated with murine SLE, but is also 
associated with human SLE. Circulating BLyS levels are 
elevated in as many as 50% of SLE patients [110], and 
disease activity correlates with blood leukocyte expres  sion 
of BLyS mRNA [111]. Aberrant expression of BLyS on 
multiple immune cells has been observed in SLE. Although 
BLyS is largely expressed in myeloid lineage cells, activated 
B cells can also express both BLyS and APRIL. In SLE 
patients, B cells and plasma cells express high levels of 
BLyS and APRIL mRNA, which correlate with disease 
activity and levels of anti-dsDNA antibodies [112].
In addition to the biologic studies summarized above, 
investigations into genetic susceptibility loci in SLE have 
revealed associations between polymorphisms in BLyS 
and APRIL genes with human SLE [113,114]. In light of 
the results from murine SLE models, from ex vivo studies 
of human SLE leukocytes, from BLyS serum analyses, 
and from the genetics of SLE, BLyS has emerged as a 
highly attractive cytokine target in SLE.
Therapeutic blockade of BLyS in human systemic lupus 
erythematosus
Th  e greatest experience to date with BLyS antagonists 
(Table  1) has accrued with belimumab, a fully human 
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Belimumab was shown to be safe in a randomized, 
double-blind, placebo-controlled phase I trial of SLE, in 
which the prevalence of adverse events was no diﬀ  erent 
between belimumab-treated and placebo-treated patients 
[116]. Of note, only modest reductions in peripheral 
blood B cells were observed among belimumab-treated 
patients. No clinical eﬃ   cacy was demonstrated in this 
phase I trial, but the small number of patients (n = 70) 
and the very brief treatment schedules (single infusion or 
two infusions 3 weeks apart) and follow-up period 
(12 weeks after ﬁ  nal infusion) precluded demonstration 
of clinical beneﬁ  t.
Disappointingly, the subsequent phase II trial (n = 449) 
failed to meet its co-primary endpoints [117]. Extensive 
post hoc analysis, however, led to a novel composite index 
of clinical response (SLE responder index) [118] and 
demonstrated signiﬁ   cantly increased clinical response 
among belimumab-treated patients at 52 weeks among 
the patients who were seropositive (ANA titer ≥1:80 and/
or positive for anti-dsDNA antibodies) at entry. Using 
this novel SLE responder index, two separate large 
randomized, double-blind, placebo-controlled phase III 
trials (n = 865 and n = 819, respectively) of belimumab in 
seropositive SLE patients each met their primary 
endpoints (increased percentage of responders at 52 weeks) 
[119,120]. Importantly, analysis of the combined 1,864 
SLE patients in both trials pointed to reductions in 
disease activity and prevention of worsening across vital 
internal organ systems [121]. Although questions remain 
regarding the durability of the clinical response, a US 
Food and Drug Administration advisory panel in 
November 2010 recommended approval for belimumab 
in the treatment of SLE, and ﬁ  nal approval by the US 
Food and Drug Administration was given on 9 March 
2011.
Concern has been raised regarding the ostensibly lower 
clinical eﬃ   cacy of belimumab in human SLE in com-
parison with the ostensibly more robust clinical eﬃ   cacy 
of BLyS antagonists in murine SLE. Th  is diﬀ  erence in 
clinical response between human and murine SLE may 
be more apparent than real. First, the clinical response in 
the phase III human trials was based on a composite of 
several instruments each rooted in multiple organ 
systems [118]. In contrast, clinical response in the murine 
trials was simply the absence of pre-moribund protein-
uria and death. (Belimumab in all likelihood will prove to 
be very eﬀ  ective in preventing pre-moribund proteinuria 
and death; however, it will take many years of follow-up 
to formally prove this point.) Second, human SLE 
patients received standard-of-care therapy in addition to 
belimumab in the human clinical trials, whereas murine 
SLE patients in the murine clinical trials received no 
treatment other than a BLyS antagonist. (Human SLE 
patients treated with belimumab alone would undoubt-
edly do much better than untreated patients, but such a 
human trial would be entirely unethical.)
In addition to belimumab, several other BLyS antago-
nists are undergoing clinical evaluation in SLE. Th  e  one 
furthest advanced in clinical evaluation is atacicept, a 
fusion protein between one of the BLyS receptors (TACI) 
and the Fc portion of IgG. Favorable safety and 
tolerability were demonstrated in a randomized, double-
blind, placebo-controlled phase I trial (n = 49) [122]. 
Dose-dependent reductions in peripheral blood B cells 
and in circulating immunoglobulin levels were noted, but 
clinical eﬃ   cacy could not be demonstrated due to the 
limited treatment and limited follow-up period. Of 
concern, an increased risk of severe infections was 
observed in a subsequent trial involving patients with 
SLE nephritis who were concurrently taking myco-
phenolate mofetil and corticosteroids (NCT00573157). 
As a consequence, this trial was prematurely terminated. 
Nevertheless, a separate phase II/III trial of atacicept in 
SLE has recently been initiated (NCT00624338). 
Whether atacicept achieves clinical success from eﬃ   cacy 
and safety standpoints remains to be determined.
A third BLyS antagonist being tested in clinical trials is 
A-623 (previously known as AMG 623), a fusion between 
the Fc portion of IgG and a peptide sequence selected for 
its ability to bind with high aﬃ   nity to BLyS. In a double-
blind, placebo-controlled phase I trial, SLE patients 
received a single dose (n = 54) or four weekly doses 
(n = 63) of escalating doses of AMG 623 or matching 
placebo [123]. A dose-independent decrease in naive and 
total peripheral blood B cells was accompanied by an 
increase in memory B cells – an observation that has now 
also been made in patients treated with atacicept or 
belimumab [122,124]. Clinical responses were not 
reported, so the relevance of the disparate changes 
among B-cell subsets to clinical parameters remains 
unknown. A phase II trial of A-623 in SLE had been 
initiated but was suspended due to ‘structural failure 
identiﬁ  ed in some product vials’, but the trial was recently 
resumed (NCT01162681).
A fourth BLyS antagonist in clinical development for 
SLE is LY2127399, a mAb that binds both soluble and 
membrane BLyS [125]. Two phase III trials in SLE are 
planned (NCT01205438 and NCT01196091), but neither 
has yet started recruiting patients. It remains to be 
determined whether neutralization of soluble plus 
membrane BLyS (as with LY2127399) will have greater 
therapeutic eﬃ   cacy than neutralization of soluble BLyS 
alone (as with belimumab).
Concluding remarks
Cytokine-targeted therapy may prove eﬀ   ective in the 
treatment of SLE and oﬀ   er less toxic options 
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gluco  corticoids or cytotoxics. In addition to the four 
cytokines reviewed above, there are many more 
cytokines – includ  ing IFNγ, IL-1, and IL-17 – that have 
been implicated in SLE. As has become painfully evident, 
cytokine biology is extremely complex – and increasingly 
so in a complex disease such as SLE. Continued 
investigations of cytokine pathways in vivo in animal 
models, ex vivo in human SLE tissues, and in the genetics 
of SLE will reveal the roles of additional cytokines in 
disease pathogenesis and should oﬀ  er additional novel 
targets for treatment.
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